Key result
Daptomycin /kg and micafungin daily for 14 days successfully cleared VRE faecium bacteremia and C. glabrata fungemia in an adult on ECMO and CRRT without requiring circuit exchange.
Why the study?
ECMO alters pharmacokinetics through changes in volume of distribution, clearance, and drug sequestration by the circuit, creating uncertainty around optimal antimicrobial dosing.
Does a specific dosing strategy of daptomycin and micafungin improve bacteremia and fungemia clearance in a patient on veno-venous ECMO and CRRT?
Case Report (n=1)
No
Does a specific dosing strategy of daptomycin and micafungin improve bacteremia and fungemia clearance in a patient on veno-venous ECMO and CRRT?
A dosing strategy of daptomycin 10 mg/kg and micafungin 150 mg daily successfully cleared VRE and C. glabrata in a patient on ECMO and CRRT without requiring circuit exchange.
Answers are grounded in this paper and cite their sources.
Successful daptomycin and micafungin dosing achieved in ECMO/CRRT patient; hypothesis-generating and requires prospective validation before broader use.
WHAT IS KNOWN AND OBJECTIVE: Studies have demonstrated that ECMO leads to pharmacokinetic changes, with alterations in volume of distribution, clearance and drug sequestration by the circuit. We describe a successful dosing approach for daptomycin and micafungin for the treatment of VRE faecium bacteremia and C. glabrata fungemia in a patient receiving veno-venous ECMO and CRRT. CASE SUMMARY: We report a case of a patient with ARDS on veno-venous ECMO complicated by VRE faecium bacteremia and C. glabrata fungemia. The patient was treated with daptomycin 10 mg/kg every 24 h and micafungin 150 mg every 24 h for 14 days. Key observations included the documented bacteremia and fungemia clearance without the need for ECMO circuit exchange. WHAT IS NEW AND CONCLUSION: This case report demonstrates successful bacteremia and fungemia clearance in an adult without the need for ECMO circuit exchange. It also highlights the need for more research to identify optimal antimicrobial dosing strategies in similar scenarios.
No takes yet. Share an insight, caveat, or question.
Cabanilla et al. (2021) conducted a case report in ARDS on veno-venous ECMO and CRRT complicated by VRE faecium bacteremia and C. glabrata fungemia (n=1). Daptomycin and micafungin was evaluated on Bacteremia and fungemia clearance. Daptomycin /kg and micafungin daily for 14 days successfully cleared VRE faecium bacteremia and C. glabrata fungemia in an adult on ECMO and CRRT without requiring circuit exchange.
Synapse has enriched 10 related papers. Consider them for comparative context: